Jie Wei,Jeffrey Jones,Jing Kang,Ananda Card,Michael Krimm,Paula Hancock,Yi Pei,Brandon Ason,Elmer Payson,Natalya Dubinina,Mark Cancilla,Mark Stroh,Julja Burchard,Alan B Sachs,Jerome H Hochman,W Michael Flanagan,Nelly A Kuklin,Alan B. Sachs,Jerome H. Hochman,W. Michael Flanagan,Nelly A. Kuklin

Abstract:Deeper knowledge of pharmacokinetic and pharmacodynamic (PK/PD) concepts for RNA therapeutics is important to streamline the drug development process and for rigorous selection of best performing drug candidates. Here we characterized the PK/PD relationship for small interfering RNAs (siRNAs) targeting luciferase by examining siRNA concentration in plasma and liver, the temporal RNA-induced silencing complex binding profiles, mRNA reduction, and protein inhibition measured by noninvasive bioluminescent imaging. A dose-dependent and time-related decrease in bioluminescence was detected over 25 days after a single treatment of a lipid nanoparticle-formulated siRNA targeting luciferase messenger RNA. A direct relationship was observed between the degree of in vivo mRNA and protein reduction and the Argonaute2 (Ago2)-bound siRNA fraction but not with the total amount of siRNA found in the liver, suggesting that the Ago2-siRNA complex is the key determinant of target inhibition. These observations were confirmed for an additional siRNA that targets endogenously expressed Sjögren syndrome antigen B (Ssb) mRNA, indicating that our observations are not limited to a transgenic mouse system. Our data provide detailed information of the temporal regulation of siRNA liver delivery, Ago2 loading, mRNA reduction, and protein inhibition that are essential for the rapid and cost-effective clinical development of siRNAs therapeutics.

Lipid-like materials for low-dose, in vivo gene silencing

Development of lipidoid–siRNA formulations for systemic delivery to the liver

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation.

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity

Lipid-Modified Aminoglycoside Derivatives for in Vivo Sirna Delivery

Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates

Mechanisms and optimization of in vivo delivery of lipophilic siRNAs

Lipopeptide Nanoparticles for Potent and Selective Sirna Delivery in Rodents and Nonhuman Primates.

Lipid‐based nanotherapeutics for siRNA delivery

Lipid-like Nanomaterials for Simultaneous Gene Expression and Silencing in Vivo.

RNA-Induced Silencing Complex-Bound Small Interfering RNA Is a Determinant of RNA Interference-Mediated Gene Silencing in Mice

Targeted Gene Silencing in Vivo by Platelet Membrane-Coated Metal-Organic Framework Nanoparticles

Hybrid Lipid–polymer Nanoparticles for Sustained Sirna Delivery and Gene Silencing

In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight

Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia

Lipid Nanoparticles for Hepatic Delivery of Small Interfering Rna

A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes

A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system

Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery

Mechanistic Insights into LDL Nanoparticle-Mediated Sirna Delivery.